Jefferies upgraded DuPont from Hold to Buy and set a new price target of $101.00 from $78.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $85.00 → $89.00 | Underweight → Equal Weight | Barclays |
| 1/17/2025 | $91.00 | Peer Perform → Outperform | Wolfe Research |
| 10/7/2024 | $88.00 → $84.00 | Equal Weight → Underweight | Barclays |
| 5/28/2024 | $85.00 → $95.00 | Neutral → Buy | Citigroup |
| 5/24/2024 | $80.00 → $103.00 | Equal Weight → Overweight | Wells Fargo |
| 5/23/2024 | $96.00 | Market Perform → Outperform | BMO Capital Markets |
| 5/17/2024 | $78.00 → $101.00 | Hold → Buy | Jefferies |
| 3/1/2024 | Peer Perform | Wolfe Research |
SC 13G/A - DuPont de Nemours, Inc. (0001666700) (Subject)
SC 13G/A - DuPont de Nemours, Inc. (0001666700) (Subject)
SC 13G - DuPont de Nemours, Inc. (0001666700) (Subject)
4 - DuPont de Nemours, Inc. (0001666700) (Issuer)
4 - DuPont de Nemours, Inc. (0001666700) (Issuer)
4 - DuPont de Nemours, Inc. (0001666700) (Issuer)
Fourth Quarter 2024 Highlights Net Sales of $3.1 billion increased 7%; organic sales increased 7% versus year-ago periodGAAP Loss from continuing operations of $(61) million, operating EBITDA of $807 millionGAAP EPS from continuing operations of $(0.17); adjusted EPS of $1.13Cash provided by operating activities from continuing operations of $564 million; transaction-adjusted free cash flow of $455 millionFull Year 2024 Highlights Net Sales of $12.4 billion increased 3%; organic sales increased 1% versus prior yearGAAP Income from continuing operations of $778 million; operating EBITDA of $3.14 billionGAAP EPS from continuing operations of $1.77; adjusted EPS of $4.07Cash provided by operati
Awards program recognizing excellence in healthcare packaging initiatives that utilize Tyvek® to help drive and promote continued sustainable innovation WILMINGTON, Del., Jan. 29, 2025 /PRNewswire/ -- DuPont (NYSE:DD) today announced that it is accepting nominations for the 2nd annual global Tyvek® Sustainable Healthcare Packaging Awards program. The awards program is designed to recognize companies and organizations across the healthcare industry who are embracing and driving sustainability throughout the packaging lifecycle. The awards program is open to any medical device
GENEVA, Switzerland, Jan. 21, 2025 /PRNewswire/ -- DuPont (NYSE:DD) today announced that DuPont™ MOLYKOTE® HP-300 Grease has successfully met rigorous hydrogen purity standards in accordance with ISO 14687:2019. In collaboration with HyCentA Research GmbH, MOLYKOTE® developed an innovative lubricant testing protocol aligned with these standards. The grease underwent several weeks of exposure to hydrogen at a pressure of 700 bar, followed by a hydrogen gas and particle contamination analysis. The results showed MOLYKOTE® HP-300 did not significantly contaminate hydrogen, ensuri
10-K - DuPont de Nemours, Inc. (0001666700) (Filer)
8-K - DuPont de Nemours, Inc. (0001666700) (Filer)
10-Q - DuPont de Nemours, Inc. (0001666700) (Filer)
Barclays upgraded DuPont from Underweight to Equal Weight and set a new price target of $89.00 from $85.00 previously
Wolfe Research upgraded DuPont from Peer Perform to Outperform and set a new price target of $91.00
Barclays downgraded DuPont from Equal Weight to Underweight and set a new price target of $84.00 from $88.00 previously
Fourth Quarter 2024 Highlights Net Sales of $3.1 billion increased 7%; organic sales increased 7% versus year-ago periodGAAP Loss from continuing operations of $(61) million, operating EBITDA of $807 millionGAAP EPS from continuing operations of $(0.17); adjusted EPS of $1.13Cash provided by operating activities from continuing operations of $564 million; transaction-adjusted free cash flow of $455 millionFull Year 2024 Highlights Net Sales of $12.4 billion increased 3%; organic sales increased 1% versus prior yearGAAP Income from continuing operations of $778 million; operating EBITDA of $3.14 billionGAAP EPS from continuing operations of $1.77; adjusted EPS of $4.07Cash provided by operati
WILMINGTON, Del., Jan. 15, 2025 /PRNewswire/ -- DuPont (NYSE:DD) will release its fourth quarter and full year 2024 financial results at 6:00 a.m. ET on Tuesday, February 11, 2025. In addition, the company will host a conference call at 8:00 a.m. ET that day. The event will be webcast live and can be accessed on DuPont's Investors Relations webpage. A replay, along with the earnings release and supporting materials, will also be posted to the website. The dial-in number for the conference call is 888-440-4172 toll-free within the U.S. or +1-646-960-0673. The conference
Net Sales of $3.2 billion increased 4%; organic sales increased 3% versus year-ago periodGAAP Income from continuing operations of $480 million; operating EBITDA of $857 millionGAAP EPS from continuing operations of $1.13; adjusted EPS of $1.18Cash provided by operating activities from continuing operations of $737 million; transaction-adjusted free cash flow of $640 millionRaises guidance for full year 2024 operating EBITDA and adjusted EPSWILMINGTON, Del., Nov. 5, 2024 /PRNewswire/ -- DuPont (NYSE:DD) announced its financial results(1) for the third quarter ended September 30, 2024.
Dr. Deyan Wang and Nicholas Sands Recognized for a Career of Innovation and Business Impact; Achieve Highest Technical Level in the Company WILMINGTON, Del., Oct. 10, 2024 /PRNewswire/ -- DuPont (NYSE:DD) today announced that two of its technology leaders have achieved the professional distinction of DuPont Laureate, the company's most distinguished technical designation. The newly appointed Laureates are Dr. Deyan Wang, DuPont Electronics & Industrial and Nicholas (Nick) Sands of DuPont Water & Protection. "I'm tremendously honored to recognize Deyan and Nick, two of DuPont's
Transaction deepens healthcare offerings in medical device solutions WILMINGTON, Del., June 25, 2024 /PRNewswire/ -- DuPont (NYSE:DD) today announced it has signed an agreement to acquire Donatelle Plastics Incorporated, a leading medical device contract manufacturer specializing in the design, development and manufacture of medical components and devices. The transaction is expected to close in the third quarter 2024, subject to satisfaction of customary closing conditions and receipt of regulatory approvals. "Our healthcare strategy is focused on offering a comprehensive sui
Ed Breen to Transition to Executive Chair Role; Lori Koch Named Chief Executive Officer; Antonella Franzen Named Chief Financial Officer WILMINGTON, Del., May 22, 2024 /PRNewswire/ -- DuPont (NYSE:DD) today announced that its Board of Directors has selected Lori D. Koch, DuPont's Chief Financial Officer, to succeed Edward D. Breen as the company's Chief Executive Officer. Effective June 1, 2024, Mr. Breen will transition from the role of CEO to full-time Executive Chairman of the Board of Directors. Additionally, Ms. Koch is expected to join the Board of Directors at its next regularly scheduled meeting in June.